632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III

SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia a randomized national fi LMC comparative trial of two therapeutic strategies

Asciminib and pregnancy in CML Preliminary human data and clinical implications from 47 reported outcomes

Asciminib for newly diagnosed chronic myeloid leukemia Results from A phase II trial

Outcomes of patients with chronic myeloid leukemia receiving second line therapy after failure of frontline second generation tyrosine kinase inhibitor

ELN milestone driven TKI switching improves deep molecular response rates in chronic myeloid leukemia

An open label randomized Study of low dose dasatinib 50 mg OD vs standard dose dasatinib 100 mg OD vs standard dose imatinib 400 mg OD as upfront therapy in patients with newly diagnosed chronic myeloid leukemia CML chronic Phase CP

Next generation sequencing from dried blood spots Spot on CML results from low and middle income countries

Intronic DNA variants in EZH2 and GATA2 predict treatment free remission in chronic myeloid leukemia patients from the destiny trial

Long term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors

Resistance to imatinib of leukemia growth in non marrow organs and eradication by dasatinib Published cases and gene clues

BCR ABL1 GUSB halving times predict molecular response to asciminib at 18 months

High rates of deep molecular response DMR in patients pts with chronic myeloid leukemia in chronic Phase CML CP who have not achieved dmr after ≥1 year of prior imatinib IMA in the asciminib ASC monotherapy arm of the Phase 2 ASC4MORE study

Predictive factors for successful treatment free remission in patients with chronic myeloid leukemia A pooled analysis

Beyond survival in chronic myeloid leukemia A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors

XS003 an amorphous re formulation of nilotinib demonstrates improved dose linearity and minimal food effect reducing the risk of QT prolongation at fed conditions

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase Result of JALSG CML RE STOP219 study

Five year interim analysis of multi institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan J SKI